Shop
eStoreRx™
Online Supplement Dispensary
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
Biotics Research is proud to expand our commitment to education with the Wellness Unfiltered Pro Podcast. Each episode delves into key health topics and the clinical applications of our premier products. Through candid, insightful conversations, our team offers practical guidance to keep you informed and empowered as a healthcare professional.
January 23 2025
Environmental Science and Technology Letters recently published an analysis of the per- and polyfluoroalkyl substances (PFAS) content of 22 different ...
A small double-blind study has revealed serum-derived bovine immunoglobulin (SBI) as a potentially safe, effective nutritional moiety in post-infectious, refractory diarrhea-predominant irritable bowel syndrome (IBS-D) and IBS with a mixed diarrhea/constipation pattern (IBS-M).
The aim of this study was to assess the safety and clinical outcomes of SBI in refractory IBS patients, and focused on patients with IBS-D and IBS-M specifically who had suffered from recurring Clostridium difficile infections (CDI).
Post-infectious IBS is thought to affect around at least 10% of IBS sufferers because they can trace the onset of their symptoms to a previous bout of infectious dysentery. Only recently has CDI been documented as a contributor to the issue worth further investigation.
In previous studies, several bacterial toxins in animals were bound with SBI. In vitro, evidence was found that SBI can bind to and neutralize C. difficile toxins A and B. However, in this small double-blind study, two patients were treated for relapsing CDI. Despite negative retesting for C. difficile, Patient 1, a 39-year-old female patient, developed persistent diarrhea and intolerance to common therapies. She actually filed for disability due to the severity of the symptoms. Patient 2 was a 57-year old female who experienced ongoing diarrhea with bouts of constipation after clearance of recurrent CDI.
The results showed that Patient 1’s frequent loose stools were completely managed within 2 weeks of starting 5 g SBI four times daily, yet returned when treatment was discontinued. She then began taking 5 g SBI daily and was able to return to work.
When Patient 2 was administered 5 g of SBI twice daily, she experienced better bowel management within just a few days. A reduced dose of SBI 5 g just once per day was provided to avoid possible constipation and the patient reported regulation of her bowel habits at that dose.
The scientists behind the results of this study suggest the need for additional research into this nutritional agent in post-C. difficile infectious IBS sufferers.
Submit this form and you'll receive our latest news and updates.
The effect of a Mediterranean diet on both gastrointestinal (GI) and psychological symptoms among people with irritable ...
Learn moreResults of a double-blind randomized controlled trial were recently published in the Journal of Pediatric Gastroenterolo...
Learn moreA recent study on both mice and human subjects has revealed the biological mechanism that explains why some people exper...
Learn more
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
Proposition 65 Warning
© 2025 Biotics Research Corporation - All Rights Reserved
Submit your comment